MB
EPIX

MPM BioImpact’s ESSA Pharma EPIX Stock Holding History

MPM BioImpact’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-405,700
Closed -$738K – 38
2022
Q3 		$738K Sell
405,700
-255,192
-39% -$672K 0.17% 36
2022
Q2 		$2.08M Hold
660,892
– – 0.58% 32
2022
Q1 		$4.08M Sell
660,892
-7,796
-1% -$68.5K 1.1% 26
2021
Q4 		$9.49M Sell
668,688
-14,599
-2% -$163K 1.73% 14
2021
Q3 		$5.47M Buy
+683,287
New +$10.9M 0.85% 25

Other funds holding EPIX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

MPM BioImpact's EPIX Position: Q4 2022 in Review

MPM BioImpact sold out of ESSA Pharma (EPIX) in Q4 2022, closing a stake of 405,700 shares — an estimated $738K sold.

MPM BioImpact first reported a position in EPIX in Q3 2021 and held it in 5 quarters. The position peaked at $9.49M in Q4 2021. 45 funds tracked by Wall St. Rank hold EPIX as of Q4 2022.

  • MPM BioImpact reported no remaining ESSA Pharma position as of Q4 2022 after selling out during the quarter.
  • MPM BioImpact sold 405,700 ESSA Pharma shares in Q4 2022, an estimated $738K.
  • MPM BioImpact first reported a position in ESSA Pharma in Q3 2021 and held it in 5 quarters.
  • MPM BioImpact's ESSA Pharma position peaked at $9.49M in Q4 2021.
  • 45 funds tracked by Wall St. Rank held ESSA Pharma as of Q4 2022.

Based on MPM BioImpact's 13F filing for Q4 2022, filed 14 Feb 2023.